Interstitial Lung Disease: How Should Therapeutics Be Implemented?

Area of Science:

• Rheumatology
• Pulmonology
• Internal Medicine

Background:

• Systemic sclerosis-interstitial lung disease (SSc-ILD) is a severe complication of systemic sclerosis (SSc), leading to significant morbidity and mortality.
• Current treatment options for SSc-ILD include cyclophosphamide, mycophenolate mofetil, tocilizumab, and nintedanib, with proven efficacy.
• The unpredictable disease course, challenges in progression assessment, and varied treatment strategies complicate clinical management.

Purpose of the Study:

• To review and synthesize current evidence regarding the monitoring and treatment of SSc-ILD.
• To identify and discuss areas where further research is critically needed for improved SSc-ILD management.

Main Methods:

• Comprehensive literature search of existing evidence on SSc-ILD monitoring and treatment.
• Synthesis and critical appraisal of the collected data.

Main Results:

• Established efficacy of certain treatments like tocilizumab and nintedanib in SSc-ILD.
• Identification of complexities in predicting and managing SSc-ILD progression.
• Summary of current monitoring strategies and treatment guidelines.

Conclusions:

• Effective management of SSc-ILD requires a thorough understanding of current evidence and ongoing research.
• Further research is essential to address the complexities in SSc-ILD monitoring, prediction, and treatment optimization.